Form 4: Ocular Therapeutix CBO Granted Significant Equity Awards

Ocular Therapeutix's Chief Business Officer, Namrata Saroj, received substantial equity grants, including restricted stock units and stock options, aligning incentives with long-term company performance.

Summary

• Namrata Saroj, Chief Business Officer of Ocular Therapeutix, Inc. (OCUL), was granted 79,112 restricted stock units (RSUs) on January 2, 2026.
• Each RSU represents a right to receive one share of the Corporation's common stock, vesting over three years (1/3 on the one-year anniversary, then 1/3 each successive year).
• An additional 240,932 stock options were granted on January 2, 2026, with an exercise price of $11.82 per share and an expiration date of January 1, 2036.
• These stock options vest over four years, with 1/48 vesting monthly beginning on the one-month anniversary of the grant date.
• The reporting person also acquired 1,373 shares of common stock under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on December 31, 2025.
• Following these transactions, Namrata Saroj beneficially owns 254,620 shares of common stock and 240,932 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates a standard executive compensation event, aligning management incentives with shareholder interests. It is generally positive for retention and long-term focus, with minor potential for future dilution.

Positives

• The equity grants align the Chief Business Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• The awards serve as a retention mechanism for a key executive, ensuring continued service and leadership.
• The grants are made under established company incentive plans, indicating a structured approach to executive compensation.

Negatives

• The issuance of new equity awards could lead to future dilution for existing shareholders as RSUs vest and options are exercised.

Risks

• The value of the granted RSUs and stock options is subject to the future performance and market price of Ocular Therapeutix's common stock.
• Vesting of both RSUs and stock options is conditional on the reporting person's continued service to the Corporation, posing a risk if employment ceases.
• Potential dilution from the exercise of stock options and vesting of RSUs could impact per-share earnings and ownership percentages.

Future Outlook

The equity grants, with their multi-year vesting schedules (3 years for RSUs, 4 years for stock options), indicate an expectation of continued service from the Chief Business Officer and are designed to incentivize long-term strategic contributions and value creation for Ocular Therapeutix.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries. It is widely used to attract, retain, and motivate key executives, aligning their interests with the long-term success and shareholder value of the company, particularly given the long development cycles and inherent risks in drug development.

Comparison to Industry Standards

• The use of restricted stock units and stock options as a significant component of executive compensation is a common practice across the biotechnology sector.
• Vesting schedules of 3-4 years for equity awards are typical in the industry, designed to promote long-term retention and performance.
• This filing does not provide specific benchmarks or details of comparable companies, projects, or results to allow for a direct quantitative comparison of the grant size or terms against industry peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution from the vesting and exercise of equity awards, but also benefit from aligned executive incentives for long-term performance.
• Employees: The filing reflects standard compensation practices, potentially impacting morale and retention by demonstrating commitment to executive incentives.
• Management: The Chief Business Officer receives significant long-term incentives tied to the company's stock performance and continued service.

Next Steps

• The Chief Business Officer's continued service to Ocular Therapeutix is required for the vesting of the granted restricted stock units and stock options.
• The company will continue to operate under its existing 2021 Stock Incentive Plan and 2014 Employee Stock Purchase Plan.

Key Dates

Keywords

OCULAR THERAPEUTIX, OCUL, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Option, Chief Business Officer, Namrata Saroj, Executive Compensation